Oncolytic Virus Immunotherapy Market

Oncolytic Virus Immunotherapy Market (Type: Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus, and Others; and Route of Administration: Intratumoral and Intravenous) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Oncolytic Virus Immunotherapy Market Outlook 2031

  • The global industry was valued at US$ 110.2 Mn in 2022
  • It is expected to advance at a CAGR of 21.1% from 2023 to 2031 and reach US$ 572.2 Mn by the end of 2031

Analyst Viewpoint

Growth in prevalence of cancer and rise in healthcare spending are primary factors augmenting the oncolytic virus immunotherapy market value. Around 40% of men and women are likely to be diagnosed with cancer at some point in their lifetime.

Under oncolytic virus therapy, viruses are used to infect and destroy cancer cells. Increase in clinical trials in oncolytic virus immunotherapy is also boosting market progress.

Companies operating in the global oncolytic virus immunotherapy market are investing in R&D activities to launch technically advanced products.

In line with the latest oncolytic virus immunotherapy industry trends, key players are partnering with research institutes to conduct clinical trials of oncolytic viruses to introduce effective drugs for different forms of cancers.

Market Introduction

Oncolytic virus immunotherapy entails usage of viruses in cancer treatment in order to infect and destroy cancer-affected cells. The naturally occurring virus is thus engineered to deliver therapeutic payloads to tumors and render immune-boosting molecules after tumor cells are infected.

Advantages of oncolytic virus immunotherapy include decrease in the burden of tumor via virus replication in tumorous cells.

Adenovirus-based oncolytic viruses are among the preferred viral vectors in oncolytic virus immunotherapy due to their capacity of inducing adaptive as well as innate immune responses, which are employed to deliver target antigens to hosts.

The ongoing market trend comprises several clinical trials of oncolytic viruses in conjunction with radiotherapy, chemotherapeutic agents, and immune checkpoint inhibitors that are showing positive results. For instance, T-VEC, RIGVIR, and Oncorine oncolytic viral drugs were approved for cancer treatment in 2020. They are reported to show positive therapeutic effects.

Growth in Incidence of Cancer and Rise in Healthcare Spending Propelling Oncolytic Virus Immunotherapy Market Size

As per the American Cancer Society’s 2021 report, 1.9 million new cases of cancer were detected in 2021, with 608,570 fatalities due to cancer in the U.S. alone.

Increase in awareness regarding cancer treatments in the wake of increasing cancer-affected population and availability of advanced immune-oncology drugs are driving the oncolytic virus immunotherapy market growth.

Improper dietary habits, lack of physical activity, obesity, and rise in consumption of tobacco and alcohol are some of the factors responsible for the growth in prevalence of cancer across the globe. Genetics also plays a key role in causing cancer.

Various countries across the globe are spending increasingly on healthcare through R&D activities. The U.S. government spends significantly on healthcare every year. As per the Centers for Medicare and Medicaid Services (CMS), the U.S. healthcare spending grew to 9.7% in 2020 as compared to that in 2019.

In Europe, oncolytic virus gene therapy for lung cancer is driving the market for oncolytic virus immunotherapy as large number of lung cancer cases were detected in 2020 alone (as stated by the National Institutes of Health). It further states that healthcare expenditure related to cancer surpassed US$ 111.2 Bn in 2020.

Positive Clinical Trial Results Creating Immense Oncolytic Virus Immunotherapy Market Opportunities

Researchers are constantly engaged in creating new clinical trials related to oncolytic virus immunotherapy in order to find ways to improve cancer treatment and outcome. Several such clinical trials have resulted in positive results such as increase in survival rates and regression of tumor.

Rise in investments in clinical trials is one of the key factors that is fostering market development. In April 2022, Mustang Bio, Inc. announced that it would initiate a phase I clinical trial that would combine oncolytic virus and CAR T cells to treat recurrent glioblastoma (rGBM).

This initiation is a result of the interim data obtained from two investigator-sponsored Phase I clinical trials that evaluated MB-108 (C134 oncolytic virus) and MB-101 (City of Hope’s targeted CAR T therapy).

Progress in clinical trials conducted by one player is encouraging other companies to opt for such trials. This, in turn, is bolstering oncolytic virus immunotherapy market demand.

Regional Outlook

As per oncolytic virus immunotherapy market analysis, North America accounted for the largest share of the global industry in 2022. The region is projected to maintain its dominant position during the forecast period.

Growth in market statistics of North America can be ascribed to the presence of a well-developed healthcare infrastructure that is conducive to clinical trials, research collaborations between market players and academia, and positive regulatory framework that fosters innovation.

In November 2021, City of Hope, a leading cancer treatment and research center, announced inauguration of the first in-human clinical trial to evaluate usage of cancer-killing oncolytic virus for treating those affected with metastatic triple-negative breast cancer.

The therapy called CF33-hNIS-antiPDL1 is devised from chimeric oncolytic orthopoxvirus, a naturally occurring virus.

Europe also constitutes substantial oncolytic virus immunotherapy market share, with Germany and the U.K. actively participating in various research programs/clinical trials to facilitate viral oncolysis.

As per the latest oncolytic virus immunotherapy market forecast, Asia Pacific is anticipated to record steady industry growth owing to the rise in research activities pertaining to oncolytic virus immunotherapy in the region.

For instance, in June 2021, Daiichi Sankyo Company Ltd. announced that it had received a conditional approval for DELYTACT, the first oncolytic virotherapy for brain cancer in the world, from the Japan Ministry of health, Labor, and Welfare.

Analysis of Key Players

Companies operating in the global oncolytic virus immunotherapy landscape are engaged in collaborations and partnerships to introduce anticancer virus therapeutics through joint research.

In September 2022, Virogin Biotech announced a strategic collaboration with the University of Texas MD Anderson Cancer Center for accelerating development of various investigational treatments, including oncolytic virus immunotherapies, and identifying prognostic biomarkers of response.

Merck & Co., Inc. (Viralytics Limited), Amgen Inc., Shanghai Sunway Biotech Co., Ltd., ILT Biotherapeutics, Oncorus, Inc., Replimune Group, Inc., Oncolys Biopharma, Inc., Sorrento Therapeutics, Inc., Oncolytics Biotech, Inc., and SillaJen, Inc. are the leading players operating in the global landscape.

The oncolytic virus immunotherapy market report highlights these players in terms of parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Key Developments in Oncolytic Virus Immunotherapy Industry

  • In January 2022, Siga Technologies announced that it had entered into a pre-clinical collaboration with Bioarchitech with the objective of devising viral immunotherapy for cancer. The research collaboration implies investigating the former’s TPOXX (tecovirimat) in conjunction with the latter’s vaccinia-based immunotherapy platform that makes use of engineered antibodies and various other proteins with oncolytic virus genome.
  • In December 2021, Bionaut Labs announced a strategic collaboration with Candel Therapeutics, Inc. to investigate utilization of the former’s remote-controlled microscale robots to precisely deliver the latter’s oncolytic viral immunotherapy agents to brain tumors
  • In August 2021, Calidi Biotherapeutics announced that it had entered into an exclusive license agreement with the University of Chicago and City of Hope to work toward oncolytic virotherapy technology

Oncolytic Virus Immunotherapy Market Snapshot

Attribute Detail
Market Size in 2022 US$ 110.2 Mn
Market Forecast (Value) in 2031 US$ 572.2 Mn
Growth Rate (CAGR) 21.1%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Mn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Type
    • Herpes Simplex Virus
    • Vaccinia Virus
    • Adenovirus
    • Reovirus
    • Others
  • Route of Administration
    • Intratumoral
    • Intravenous
  • Application
    • Melanoma
    • Non-small Cell Lung Cancer (NSCLC)
    • Pancreatic Cancer
    • Breast Cancer
    • Others
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC
Companies Profiled
  • Merck & Co., Inc. (Viralytics Limited)
  • Amgen Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • TILT Biotherapeutics
  • Oncorus, Inc.
  • Replimune Group, Inc.
  • Oncolys Biopharma, Inc.
  • Sorrento Therapeutics, Inc.
  • Oncolytics Biotech, Inc.
  • SillaJen, Inc.
Customization Scope Available Upon Request
Pricing Available Upon Request

Frequently Asked Questions

How big was the global oncolytic virus immunotherapy market in 2022?

It was valued at US$ 110.2 Mn in 2022

How is the oncolytic virus immunotherapy business expected to grow during the forecast period?

It is projected to advance at a CAGR of 21.1% from 2023 to 2031

What are the key factors driving the demand for oncolytic virus immunotherapy?

Growth in incidence of cancer, rise in healthcare spending, and positive trial results

Which oncolytic virus immunotherapy route of administration segment held the largest share in 2022?

The intravenous segment accounted for the largest share in 2022

Which region dominated the global oncolytic virus immunotherapy landscape in 2022?

North America was the dominant region in 2022

Who are the key oncolytic virus immunotherapy drugs manufacturers?

Merck & Co., Inc. (Viralytics Limited), Amgen Inc., Shanghai Sunway Biotech Co., Ltd., ILT Biotherapeutics, Oncorus, Inc., Replimune Group, Inc., Oncolys Biopharma, Inc., Sorrento Therapeutics, Inc., Oncolytics Biotech, Inc., and SillaJen, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Oncolytic Virus Immunotherapy Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, 2017-2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Type, 2017-2031

            6.3.1. Herpes Simplex Virus

            6.3.2. Vaccinia Virus

            6.3.3. Adenovirus

            6.3.4. Reovirus

            6.3.5. Others

        6.4. Market Attractiveness Analysis, by Type

    7. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Route of Administration

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Route of Administration, 2017-2031

            7.3.1. Intratumoral

            7.3.2. Intravenous

        7.4. Market Attractiveness Analysis, by Route of Administration

    8. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Application

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Application, 2017-2031

            8.3.1. Melanoma

            8.3.2. Non-small Cell Lung Cancer (NSCLC)

            8.3.3. Pancreatic Cancer

            8.3.4. Breast Cancer

            8.3.5. Others

        8.4. Market Attractiveness Analysis, by Route of Administration

    9. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017-2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Oncolytic Virus Immunotherapy Market Analysis and Forecast

        10.1. Introduction

        10.2. Key Findings

        10.3. Market Value Forecast, by Type, 2017-2031

            10.3.1. Herpes Simplex Virus

            10.3.2. Vaccinia Virus

            10.3.3. Adenovirus

            10.3.4. Reovirus

            10.3.5. Others

        10.4. Market Value Forecast, by Route of Administration, 2017-2031

            10.4.1. Intratumoral

            10.4.2. Intravenous

        10.5. Market Value Forecast, by Application, 2017-2031

            10.5.1. Melanoma

            10.5.2. Non-small Cell Lung Cancer (NSCLC)

            10.5.3. Pancreatic Cancer

            10.5.4. Breast Cancer

            10.5.5. Others

        10.6. Market Value Forecast, by Country, 2017-2031

            10.6.1. U.S.

            10.6.2. Canada

        10.7. Market Attractiveness Analysis

            10.7.1. By Type

            10.7.2. By Route of Administration

            10.7.3. By Application

            10.7.4. By Country

    11. Europe Oncolytic Virus Immunotherapy Market Analysis and Forecast

        11.1. Introduction

        11.2. Key Findings

        11.3. Market Value Forecast, by Type, 2017-2031

            11.3.1. Herpes Simplex Virus

            11.3.2. Vaccinia Virus

            11.3.3. Adenovirus

            11.3.4. Reovirus

            11.3.5. Others

        11.4. Market Value Forecast, by Route of Administration, 2017-2031

            11.4.1. Intratumoral

            11.4.2. Intravenous

        11.5. Market Value Forecast, by Application, 2017-2031

            11.5.1. Melanoma

            11.5.2. Non-small Cell Lung Cancer (NSCLC)

            11.5.3. Pancreatic Cancer

            11.5.4. Breast Cancer

            11.5.5. Others

        11.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            11.6.1. Germany

            11.6.2. U.K.

            11.6.3. France

            11.6.4. Italy

            11.6.5. Spain

            11.6.6. Rest of Europe

        11.7. Market Attractiveness Analysis

            11.7.1. By Type

            11.7.2. By Route of Administration

            11.7.3. By Application

            11.7.4. By Country/Sub-region

    12. Asia Pacific Oncolytic Virus Immunotherapy Market Analysis and Forecast

        12.1. Introduction

        12.2. Key Findings

        12.3. Market Value Forecast, by Type, 2017-2031

            12.3.1. Herpes Simplex Virus

            12.3.2. Vaccinia Virus

            12.3.3. Adenovirus

            12.3.4. Reovirus

            12.3.5. Others

        12.4. Market Value Forecast, by Route of Administration, 2017-2031

            12.4.1. Intratumoral

            12.4.2. Intravenous

        12.5. Market Value Forecast, by Application, 2017-2031

            12.5.1. Melanoma

            12.5.2. Non-small Cell Lung Cancer (NSCLC)

            12.5.3. Pancreatic Cancer

            12.5.4. Breast Cancer

            12.5.5. Others

        12.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            12.6.1. China

            12.6.2. Japan

            12.6.3. India

            12.6.4. Australia & New Zealand

            12.6.5. Rest of Asia Pacific

        12.7. Market Attractiveness Analysis

            12.7.1. By Type

            12.7.2. By Route of Administration

            12.7.3. By Application

            12.7.4. By Country/Sub-region

    13. Latin America Oncolytic Virus Immunotherapy Market Analysis and Forecast

        13.1. Introduction

        13.2. Key Findings

        13.3. Market Value Forecast, by Type, 2017-2031

            13.3.1. Herpes Simplex Virus

            13.3.2. Vaccinia Virus

            13.3.3. Adenovirus

            13.3.4. Reovirus

            13.3.5. Others

        13.4. Market Value Forecast, by Route of Administration, 2017-2031

            13.4.1. Intratumoral

            13.4.2. Intravenous

        13.5. Market Value Forecast, by Application, 2017-2031

            13.5.1. Melanoma

            13.5.2. Non-small Cell Lung Cancer (NSCLC)

            13.5.3. Pancreatic Cancer

            13.5.4. Breast Cancer

            13.5.5. Others

        13.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.6.1. Brazil

            13.6.2. Mexico

            13.6.3. Rest of Latin America

        13.7. Market Attractiveness Analysis

            13.7.1. By Type

            13.7.2. By Route of Administration

            13.7.3. By Application

            13.7.4. By Country/Sub-region

    14. Middle East & Africa Oncolytic Virus Immunotherapy Market Analysis and Forecast

        14.1. Introduction

        14.2. Key Findings

        14.3. Market Value Forecast, by Type, 2017-2031

            14.3.1. Herpes Simplex Virus

            14.3.2. Vaccinia Virus

            14.3.3. Adenovirus

            14.3.4. Reovirus

            14.3.5. Others

        14.4. Market Value Forecast, by Route of Administration, 2017-2031

            14.4.1. Intratumoral

            14.4.2. Intravenous

        14.5. Market Value Forecast, by Application, 2017-2031

            14.5.1. Melanoma

            14.5.2. Non-small Cell Lung Cancer (NSCLC)

            14.5.3. Pancreatic Cancer

            14.5.4. Breast Cancer

            14.5.5. Others

        14.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.6.1. GCC Countries

            14.6.2. South Africa

            14.6.3. Rest of Middle East & Africa

        14.7. Market Attractiveness Analysis

            14.7.1. By Type

            14.7.2. By Route of Administration

            14.7.3. By Application

            14.7.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

        15.2. Market Share Analysis, by Company (2022)

        15.3. Company Profiles

            15.3.1. Amgen Inc.

                15.3.1.1. Company Overview

                15.3.1.2. Product Portfolio

                15.3.1.3. SWOT Analysis

                15.3.1.4. Financial Overview

                15.3.1.5. Strategic Overview

            15.3.2. Merck & Co., Inc. (Viralytics Limited)

                15.3.2.1. Company Overview

                15.3.2.2. Product Portfolio

                15.3.2.3. SWOT Analysis

                15.3.2.4. Financial Overview

                15.3.2.5. Strategic Overview

            15.3.3. Shanghai Sunway Biotech Co., Ltd.

                15.3.3.1. Company Overview

                15.3.3.2. Product Portfolio

                15.3.3.3. SWOT Analysis

                15.3.3.4. Financial Overview

                15.3.3.5. Strategic Overview

            15.3.4. TILT Biotherapeutics

                15.3.4.1. Company Overview

                15.3.4.2. Product Portfolio

                15.3.4.3. SWOT Analysis

                15.3.4.4. Financial Overview

                15.3.4.5. Strategic Overview

            15.3.5. Oncorus, Inc.

                15.3.5.1. Company Overview

                15.3.5.2. Product Portfolio

                15.3.5.3. SWOT Analysis

                15.3.5.4. Financial Overview

                15.3.5.5. Strategic Overview

            15.3.6. Replimune Group, Inc.

                15.3.6.1. Company Overview

                15.3.6.2. Product Portfolio

                15.3.6.3. SWOT Analysis

                15.3.6.4. Financial Overview

                15.3.6.5. Strategic Overview

            15.3.7. Oncolys Biopharma, Inc.

                15.3.7.1. Company Overview

                15.3.7.2. Product Portfolio

                15.3.7.3. SWOT Analysis

                15.3.7.4. Financial Overview

                15.3.7.5. Strategic Overview

            15.3.8. Sorrento Therapeutics, Inc.

                15.3.8.1. Company Overview

                15.3.8.2. Product Portfolio

                15.3.8.3. SWOT Analysis

                15.3.8.4. Financial Overview

                15.3.8.5. Strategic Overview

            15.3.9. Oncolytics Biotech, Inc.

                15.3.9.1. Company Overview

                15.3.9.2. Product Portfolio

                15.3.9.3. SWOT Analysis

                15.3.9.4. Financial Overview

                15.3.9.5. Strategic Overview

            15.3.10. SillaJen, Inc.

                15.3.10.1. Company Overview

                15.3.10.2. Product Portfolio

                15.3.10.3. SWOT Analysis

                15.3.10.4. Financial Overview

                15.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031

    Table 02: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 03: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031

    Table 04: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Region, 2017-2031

    Table 05: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2017-2031

    Table 06: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031

    Table 07: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 08: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031

    Table 09: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 10: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031

    Table 11: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 12: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031

    Table 13: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 14: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031

    Table 15: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 16: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031

    Table 17: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 18: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031

    Table 19: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 20: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031

    Table 21: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031

    Table 23: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 24: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031

    List of Figures

    Figure 01: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) and Distribution (%), by Region, 2022-2031

    Figure 02: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Type, 2022

    Figure 03: Global Oncolytic Virus Immunotherapy Market Value Share, by Type, 2022

    Figure 04: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Route of Administration, 2022

    Figure 05: Global Oncolytic Virus Immunotherapy Market Value Share, by Route of Administration, 2022

    Figure 06: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Application, 2022

    Figure 07: Global Oncolytic Virus Immunotherapy Market Value Share, by Application, 2022

    Figure 08: Global Oncolytic Virus Immunotherapy Market Value Share, by Region, 2022

    Figure 09: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, 2023-2031

    Figure 10: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031

    Figure 11: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031

    Figure 12: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031

    Figure 13: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 14: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031

    Figure 15: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2022-2031

    Figure 16: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Region, 2022-2031

    Figure 17: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Region, 2022-2031

    Figure 18: North America Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 19: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country, 2023-2031

    Figure 20: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country, 2022-2031

    Figure 21: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031

    Figure 22: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031

    Figure 23: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031

    Figure 24: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031

    Figure 25: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 26: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031

    Figure 27: Europe Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 28: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 29: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031

    Figure 30: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031

    Figure 31: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031

    Figure 32: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031

    Figure 33: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031

    Figure 34: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 35: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031

    Figure 36: Asia Pacific Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 37: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 38: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031

    Figure 39: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031

    Figure 40: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031

    Figure 41: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031

    Figure 42: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031

    Figure 43: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 44: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031

    Figure 45: Latin America Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 46: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 47: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031

    Figure 48: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031

    Figure 49: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031

    Figure 50: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031

    Figure 51: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031

    Figure 52: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 53: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031

    Figure 54: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

    Figure 55: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 56: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031

    Figure 57: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031

    Figure 58: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031

    Figure 59: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031

    Figure 60: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031

    Figure 61: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 62: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031

Copyright © Transparency Market Research, Inc. All Rights reserved